Publicacions (166) Publicacions de José Luis Pérez Gracia

2024

  1. Case–control study assessing the impact of COVID19 in advanced kidney cancer patients treated with antiangiogenics or immunotherapy: the COVID-REN study

    Clinical and Translational Oncology, Vol. 26, Núm. 3, pp. 732-738

  2. Dendritic Cells in Cancer Immunology and Immunotherapy

    Cancers, Vol. 16, Núm. 5

  3. Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors

    Clinical Cancer Research, Vol. 30, Núm. 8, pp. 1630-1641

  4. Whole exome sequencing and machine learning germline analysis of individuals presenting with extreme phenotypes of high and low risk of developing tobacco-associated lung adenocarcinoma

    eBioMedicine, Vol. 102

2023

  1. A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer

    Clinical Cancer Research, Vol. 29, Núm. 17, pp. 3292-3300

  2. CD137 (4-1BB) requires physically associated cIAPs for signal transduction and antitumor effects

    Science advances, Vol. 9, Núm. 33, pp. eadf6692

  3. Intratumoral BO-112 in combination with radiotherapy synergizes to achieve CD8 T-cell-mediated local tumor control

    Journal for immunotherapy of cancer, Vol. 11, Núm. 1

  4. PSA reactivity in extracellular microvesicles to commercial immunoassays

    Clinica Chimica Acta, Vol. 543

  5. Reply to letter to the editor “Bureaucracy or Streamlining the Rules in “Good Clinical Practice (GCP)” - Has Equipoise Occurred?” by H. K. Kotikonda, V. G. Jonnalagadda and S. R. Venna

    Annals of Oncology

  6. Streamlining clinical research: an ESMO awareness call to improve sponsoring and monitoring of clinical trials

    Annals of Oncology, Vol. 34, Núm. 1, pp. 70-77

  7. Systemic treatment for brain metastasis in HER2- positive advanced breast cancer: what have we learned so far?

    Oncotarget

2022

  1. Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade

    Journal for immunotherapy of cancer, Vol. 10, Núm. 5

  2. Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis

    Cancer Letters, Vol. 529, pp. 70-84

  3. Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study

    The Lancet Oncology, Vol. 23, Núm. 2, pp. 248-258

  4. Molecular Biomarkers of Prognosis in Advanced Renal Cell Carcinoma Patients Treated With Pazopanib Plus Interferon Alpha (INF-2A) in a Phase I/II Study by the Spanish Oncology Genitourinary Group

    Clinical Genitourinary Cancer, Vol. 20, Núm. 4, pp. 388.e1-388.e10

  5. Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial

    Journal for immunotherapy of cancer, Vol. 10, Núm. 8

  6. Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies

    Journal for immunotherapy of cancer, Vol. 10, Núm. 3

2021

  1. A model based on the quantification of complement C4c, CYFRA 21-1 and CRP exhibits high specificity for the early diagnosis of lung cancer

    Translational Research, Vol. 233, pp. 77-91

  2. A multidisciplinary consensus on the morphological and functional responses to immunotherapy treatment

    Clinical and Translational Oncology, Vol. 23, Núm. 3, pp. 434-449

  3. Atezolizumab in locally advanced or metastatic urothelial cancer: a pooled analysis from the Spanish patients of the IMvigor 210 cohort 2 and 211 studies

    Clinical and Translational Oncology, Vol. 23, Núm. 4, pp. 882-891